Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut. Biohaven Ltd. was formerly a subsidiary of Biohaven Pharmaceutical Holding Company Ltd. more
Time Frame | BHVN | Sector | S&P500 |
---|---|---|---|
1-Week Return | -3.58% | 1.76% | -2.5% |
1-Month Return | -2.57% | 0.33% | -3.91% |
3-Month Return | -28.97% | -8.58% | -0.59% |
6-Month Return | -2.52% | -4.26% | 3.45% |
1-Year Return | -15.96% | 1.27% | 22.31% |
3-Year Return | 413.42% | 5.33% | 25% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | 462.51M | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | - | 72.00K | 91.66M | 1.39M | 3.37M | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":0.08,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":1.51,"profit":true},{"date":"2023-12-31","value":3.68,"profit":true}] |
Gross Profit | - | (72.00K) | 370.85M | (1.39M) | (3.37M) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-0.02,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-0.37,"profit":false},{"date":"2023-12-31","value":-0.91,"profit":false}] |
Gross Margin | - | - | 80.18% | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Operating Expenses | 479.12M | 114.51M | 218.90M | 567.93M | 436.05M | [{"date":"2019-12-31","value":84.36,"profit":true},{"date":"2020-12-31","value":20.16,"profit":true},{"date":"2021-12-31","value":38.54,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":76.78,"profit":true}] |
Operating Income | (479.12M) | (114.51M) | (218.90M) | (567.93M) | (436.05M) | [{"date":"2019-12-31","value":-47912200000,"profit":false},{"date":"2020-12-31","value":-11450600000,"profit":false},{"date":"2021-12-31","value":-21890000000,"profit":false},{"date":"2022-12-31","value":-56793200000,"profit":false},{"date":"2023-12-31","value":-43605100000,"profit":false}] |
Total Non-Operating Income/Expense | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Pre-Tax Income | (528.39M) | (118.67M) | (212.43M) | (569.84M) | (409.55M) | [{"date":"2019-12-31","value":-52838600000,"profit":false},{"date":"2020-12-31","value":-11866800000,"profit":false},{"date":"2021-12-31","value":-21243000000,"profit":false},{"date":"2022-12-31","value":-56984100000,"profit":false},{"date":"2023-12-31","value":-40955100000,"profit":false}] |
Income Taxes | 419.00K | (134.30K) | 1.37M | 438.00K | (1.38M) | [{"date":"2019-12-31","value":30.67,"profit":true},{"date":"2020-12-31","value":-9.83,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":32.06,"profit":true},{"date":"2023-12-31","value":-101.24,"profit":false}] |
Income After Taxes | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Income From Continuous Operations | - | (118.67M) | (848.40M) | (570.28M) | (408.17M) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-11866800000,"profit":false},{"date":"2021-12-31","value":-84839600000,"profit":false},{"date":"2022-12-31","value":-57027900000,"profit":false},{"date":"2023-12-31","value":-40816800000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (528.80M) | (118.67M) | (213.80M) | (570.28M) | (408.17M) | [{"date":"2019-12-31","value":-52880500000,"profit":false},{"date":"2020-12-31","value":-11866800000,"profit":false},{"date":"2021-12-31","value":-21379600000,"profit":false},{"date":"2022-12-31","value":-57027900000,"profit":false},{"date":"2023-12-31","value":-40816800000,"profit":false}] |
EPS (Diluted) | (10.97) | (13.04) | (13.08) | (14.25) | (5.66) | [{"date":"2019-12-31","value":-1097,"profit":false},{"date":"2020-12-31","value":-1304,"profit":false},{"date":"2021-12-31","value":-1308,"profit":false},{"date":"2022-12-31","value":-1425,"profit":false},{"date":"2023-12-31","value":-566,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
BHVN | |
---|---|
Cash Ratio | 2.49 |
Current Ratio | 2.89 |
Quick Ratio | 2.93 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
BHVN | |
---|---|
ROA (LTM) | -118.79% |
ROE (LTM) | -265.45% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
BHVN | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.38 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.62 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
BHVN | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 11.75 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
Biohaven Pharmaceutical Holding Co Ltd (BHVN) share price today is $37.48
Yes, Indians can buy shares of Biohaven Pharmaceutical Holding Co Ltd (BHVN) on Vested. To buy Biohaven Pharmaceutical Holding Co Ltd from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in BHVN stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Biohaven Pharmaceutical Holding Co Ltd (BHVN) via the Vested app. You can start investing in Biohaven Pharmaceutical Holding Co Ltd (BHVN) with a minimum investment of $1.
You can invest in shares of Biohaven Pharmaceutical Holding Co Ltd (BHVN) via Vested in three simple steps:
The 52-week high price of Biohaven Pharmaceutical Holding Co Ltd (BHVN) is $62.21. The 52-week low price of Biohaven Pharmaceutical Holding Co Ltd (BHVN) is $26.8.
The price-to-earnings (P/E) ratio of Biohaven Pharmaceutical Holding Co Ltd (BHVN) is
The price-to-book (P/B) ratio of Biohaven Pharmaceutical Holding Co Ltd (BHVN) is 11.75
The dividend yield of Biohaven Pharmaceutical Holding Co Ltd (BHVN) is 0.00%
The market capitalization of Biohaven Pharmaceutical Holding Co Ltd (BHVN) is $3.56B
The stock symbol (or ticker) of Biohaven Pharmaceutical Holding Co Ltd is BHVN